Updates in Relapsed/Refractory Metastatic Renal Cell Carcinoma: An OncLive® Scientific Interchange and Workshop

home / publications / supplements / utilizing-tkis-in-renal-cell-carcinoma
Robert J. Motzer, MD, Memorial Sloan Kettering Cancer Center

Expert Perspectives in the Evolving Treatment Landscape for Metastatic Renal Cell Carcinoma

October 14th 2020
Article

Robert J. Motzer, MD, and Ulka Nitin Vaishampayan, MD, MBBS, FAB, discuss some of the latest updates in metastatic renal cell carcinoma.

Renal Cell Carcinoma

Updates in Relapsed/Refractory Metastatic Renal Cell Carcinoma

October 13th 2020
Article

Targeted therapy and immunotherapy have improved survival outcomes for patients with metastatic renal cell carcinoma.

Dr. Pal on the Rationale for the TIVO-3 Trial With Tivozanib in Advanced RCC

Dr. Pal on the Rationale for the TIVO-3 Trial With Tivozanib in Advanced RCC

Sumanta Kumar Pal, MD
September 15th 2020
Video

Sumanta K. Pal, MD, discusses the rationale behind the phase 3 TIVO-3 trial with tivozanib in advanced renal cell carcinoma.

Dr. Motzer on the TIVO-1 Trial With Tivozanib in Advanced RCC

Dr. Motzer on the TIVO-1 Trial With Tivozanib in Advanced RCC

Robert J. Motzer, MD
September 15th 2020
Video

Robert J. Motzer, MD, discusses the phase 3 TIVO-1 trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Dr. Vaishampayan on the Safety of Tivozanib Versus Sorafenib in RCC

Dr. Vaishampayan on the Safety of Tivozanib Versus Sorafenib in RCC

Ulka N. Vaishampayan, MBBS, FAB
September 15th 2020
Video

Ulka N. Vaishampayan, MBBS, FAB, discusses the safety of tivozanib versus sorafenib in advanced renal cell carcinoma.

Dr. Pal on the Benefit of Tivozanib in Later-Line Settings for Refractory RCC

Dr. Pal on the Benefit of Tivozanib in Later-Line Settings for Refractory RCC

Sumanta Kumar Pal, MD
September 10th 2020
Video

Sumanta K. Pal, MD, discusses the benefit of tivozanib in later-line setting treatment settings for patients with refractory renal cell carcinoma.

Dr. Vaishampayan on the Potential of Tivozanib in Advanced RCC

Dr. Vaishampayan on the Potential of Tivozanib in Advanced RCC

Ulka N. Vaishampayan, MBBS, FAB
September 9th 2020
Video

Ulka N. Vaishampayan, MBBS, FAB, discusses the potential of tivozanib in advanced renal cell carcinoma.

Dr. Motzer on the TIVO-3 Trial Examining Tivozanib in Advanced RCC

Dr. Motzer on the TIVO-3 Trial Examining Tivozanib in Advanced RCC

Robert J. Motzer, MD
September 2nd 2020
Video

Robert J. Motzer, MD, discusses the results of the phase 3 TIVO-3 trial with tivozanib versus sorafenib in patients with advanced renal cell carcinoma.

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCC

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCC

Ulka N. Vaishampayan, MBBS, FAB
August 27th 2020
Video

Ulka N. Vaishampayan, MBBS, FAB, discusses the benefit of axitinib and pembrolizumab in advanced renal cell carcinoma.